Skip to main content
. 2019 Nov 6;26(5):503–510. doi: 10.5603/CJ.a2018.0028

Table 1.

Baseline patient characteristics, demographics, background medications, efficacy and safety endpoints parameters in renal denervation and control groups.

Renal denervation group (n = 30) Control group (n = 30) P
Age [years] 59.0 (12.1) 61.3 (11.1) 0.446
Sex [male] 25 (83.3%) 22 (73%) 0.347
Body mass index [kg/m2] 26.8 (2.6) 26.7 (2.8) 0.939
Medical history:
 Hypertension 21 (70.0%) 18 (60.0%) 0.417
 Coronary heart disease 17 (56.7%) 18 (60.0%) 0.793
 Atrial fibrillation 4 (13.3%) 3 (10.0%) 0.688
 Type 2 diabetes 8 (26.7%) 7 (23.3%) 0.766
Patients receiving drug class:
 ACE or ARB 29 (96.7%) 28 (93.3%) 1.000
 Beta-blockers 23 (76.7%) 24 (80.0%) 0.754
 Aldosterone antagonists 6 (20.0%) 4 (13.3%) 0.488
 Calcium-channel blockers 14 (46.7%) 12 (40.0%) 0.602
 Digoxin 3 (10%) 1 (3.3%) 0.612
 Loop diuretics 14 (46.7%) 16 (53.3%) 0.606
Hemoglobin 119.1 (25.9) 112.3 (24.5) 0.299
Efficacy endpoint:
 NT-proBNP [pg/mL] 797.7 (356.1) 784.7 (377.1) 0.892
 Six minute walk test [m] 217.5 (69.5) 210.0 (63.0) 0.666
 NYHA class:
  Class II 17 (56.7%) 16 (53.3%) 0.795
  Class III 13 (43.3%) 14 (46.7%) 0.795
 Echocardiographic LVEF [%] 35.0 (3.2) 34.8 (3.2) 0.872
Safety endpoint:
 GFR [mL/min/1.73 m2] 104.8 (35.9) 96.4 (31.8) 0.337
 Symbolic BP [mmHg] 142.0 (24.8) 143.2 (20.7) 0.844
 Diastolic BP [mmHg] 79.8 (12.6) 81.7 (12.9) 0.579
 Heart rate [bpm] 68.7 (7.9) 69.4 (6.9) 0.728

Data are mean (standard deviation) or number (%). ACE — angiotensin-converting enzyme inhibitor; ARB — angiotensin II receptor blocker; BP — blood pressure; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal pro-B-type natriuretic peptide; NYHA — New York Heart Association